Crofelemer for the treatment of secretory diarrhea

@article{Cottreau2012CrofelemerFT,
  title={Crofelemer for the treatment of secretory diarrhea},
  author={Jessica M. Cottreau and Anne M Tucker and Rustin D. Crutchley and Kevin W. Garey},
  journal={Expert Review of Gastroenterology \& Hepatology},
  year={2012},
  volume={6},
  pages={17 - 23}
}
Secretory diarrhea is a leading cause of morbidity and mortality worldwide. Crofelemer is a first-in-class antidiarrheal agent that simultaneously targets two distinct channels, the cystic fibrosis conductance regulator and calcium-activated chloride channel, responsible for chloride and fluid secretion in the GI tract. Crofelemer is a novel compound extracted from the stem bark latex of the Croton lechleri tree found in the western Amazonian region of South America. There is little to no… 
Crofelemer, a novel agent for treatment of non-infectious diarrhea in HIV-infected persons
Crofelemer is the first US FDA-approved drug for symptomatic relief in HIV-infected persons on antiretroviral therapy (ART) who have non-infectious diarrhea. With the availability of ART, there is
Crofelemer: A Review of its Use in the Management of Non-Infectious Diarrhoea in Adult Patients with HIV/AIDS on Antiretroviral Therapy
TLDR
Crofelemer is the first (and so far only) agent to be approved by the US FDA specifically for the symptomatic relief of non-infectious (i.e. secretory) diarrhoea in adult patients with HIV/AIDS on antiretroviral therapy (ART).
Empiric treatment of diarrhea in patient with HIV infection: a case report
TLDR
A 31 years old male patient with 3 days fatigue and diarrhea is diagnosed and metronidazole is available for the management of diarrhea in patient with HIV that can’t be treated with other antibiotics.
Convective washout reduces the antidiarrheal efficacy of enterocyte surface–targeted antisecretory drugs
TLDR
A convection–diffusion model of washout in an anatomically accurate three-dimensional model of human intestine comprising cylindrical crypts and villi secreting fluid into a central lumen is developed and predicted greatly reduced inhibitor efficacy for high crypt fluid secretion as occurs in cholera.
Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy
TLDR
A concise evaluation of a newly approved medication (crofelemer) that has a novel mechanism of action and has received approval for the symptomatic relief of non-infectious diarrhea in adult patients with HIV on anti-retroviral therapy is provided.
Noninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral Therapy
TLDR
Approaching management using a stepwise method of nonpharmacologic (diet), nonprescription (over-the-counter) and prescription agent changes (modification of cART or addition of an evidence-based antidiarrheal) appears reasonable, despite a lack of clear scientific evidence to support the initial two steps of this approach.
Antibacterial and Antidiarrheal Activities of Plant Products against Enterotoxinogenic Escherichia coli
TLDR
This review gathers the scattered information on the antidiarrheal activities reported for various plant products on ETEC and their enterotoxins, which includes two major effects: The inhibitory effect on bacterial growth or viability and the interference with ETEC enterotoxin activity upon the intestinal epithelium.
Improved Electrolyte and Fluid Balance Results in Control of Diarrhea with Crofelemer in Patient with Short Bowel Syndrome: A Case Report
  • Powers William
  • Medicine
    Journal of Clinical Gastroenterology and Treatment
  • 2022
TLDR
Off-label treatment with crofelemer, an FDA-approved antidiarrheal with a novel mechanism of action, resulted in near-immediate relief and improved stool consistency resulting in significant normalization of bowel movements in a 55-year-old female with chronic, severe diarrhea.
Evaluation of oral serum-derived bovine immunoglobulins in HIV-infected patients with chronic idiopathic diarrhea
TLDR
Oral SBI is safe and well tolerated at the doses studied in HIV patients with chronic diarrhea, and GI symptom improvements were maintained throughout the 20-week PBO-free phase.
...
...

References

SHOWING 1-10 OF 28 REFERENCES
How do the rotavirus NSP4 and bacterial enterotoxins lead differently to diarrhea?
TLDR
A solution to this riddle was that intestinal villi do in fact secrete chloride as a result of rotavirus infection, and the overall chloride secretory response is regulated by a phospholipase C-dependent calcium signaling pathway induced by NSP4.
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
TLDR
Crofelelmer did not produce benefit on bowel function; an increase in the number of pain- and discomfort-free days in female D-IBS patients was seen; further studies with crofelemer are warranted to evaluate it as a potential visceral analgesic.
Crofelemer, an Antisecretory Antidiarrheal Proanthocyanidin Oligomer Extracted from Croton lechleri, Targets Two Distinct Intestinal Chloride Channels
TLDR
The dual inhibitory action of crofelemer on two structurally unrelated prosecretory intestinal Cl− channels may account for its intestinal antisecretory activity.
Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea.
  • C. Ericsson
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
The antisecretory and antimotility agent loperamide reduces the passage of loose stools by approximately 50% and has been especially useful, in combination with antimicrobial agents, in reducing the total duration of posttreatment diarrhea to a matter of hours.
A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico
TLDR
SP-303 was effective in shortening the duration of travelers' diarrhea by 21%.
Use of bismuth subsalicylate for the prevention of travelers' diarrhea.
During the months of July 1977 and July 1985, students from the United States participated in a double-blind, placebo-controlled trial examining the effectiveness of liquid bismuth subsalicylate
Activation of intestinal CFTR Cl‐ channel by heat‐stable enterotoxin and guanylin via cAMP‐dependent protein kinase.
TLDR
It is shown that STa, guanylin and cGMP each activate intestinal Cl‐ secretion, and that this is abolished by inhibitors of cAMP‐dependent protein kinase (PKA), suggesting that PKA is a major mediator of this effect.
...
...